Details of the Drug

General Information of Drug (ID: DMRICNP)

Drug Name
Vandetanib
Synonyms
Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EX04: Vandetanib
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 475.4
Logarithm of the Partition Coefficient (xlogp) 4.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 19 days [3]
Metabolism
The drug is metabolized via plasma []
Vd
The volume of distribution (Vd) of drug is 7450 L []
Chemical Identifiers
Formula
C22H24BrFN4O2
IUPAC Name
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Canonical SMILES
CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
InChI
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChIKey
UHTHHESEBZOYNR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3081361
ChEBI ID
CHEMBL24828
CAS Number
443913-73-3
UNII
YO460OQ37K
DrugBank ID
DB05294
TTD ID
D0G6QF
VARIDT ID
DR00618
INTEDE ID
DR1669
ACDINA ID
D00720
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [4]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [4]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Gene/Protein Processing [8]
Calbindin (CALB1) OTM7IXDG CALB1_HUMAN Gene/Protein Processing [8]
Collagen alpha-3(IV) chain (COL4A3) OT6SB8X5 CO4A3_HUMAN Gene/Protein Processing [8]
DNA mismatch repair protein Msh3 (MSH3) OTD3YPVL MSH3_HUMAN Gene/Protein Processing [8]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Gene/Protein Processing [8]
Histone H1.2 (H1-2) OT0AVI4M H12_HUMAN Gene/Protein Processing [8]
Hypoxia-inducible lipid droplet-associated protein (HILPDA) OTEID3ZM HLPDA_HUMAN Gene/Protein Processing [8]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Gene/Protein Processing [8]
Insulin-induced gene 2 protein (INSIG2) OTX4VY51 INSI2_HUMAN Gene/Protein Processing [8]
Phosphoglycerate kinase 1 (PGK1) OT6V1ICH PGK1_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 9.69E-01 1.16E-03 3.56E-03
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.15E-01 6.20E-03 5.61E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vandetanib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [9]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Vandetanib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [10]
Coadministration of a Drug Treating the Disease Different from Vandetanib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ivosidenib. Acute myeloid leukaemia [2A60] [10]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Vandetanib and Midostaurin. Acute myeloid leukaemia [2A60] [10]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Vandetanib and Arn-509. Acute myeloid leukaemia [2A60] [10]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Vandetanib and Oliceridine. Acute pain [MG31] [10]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Ivabradine. Angina pectoris [BA40] [11]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Vandetanib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [10]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Vandetanib and Levalbuterol. Asthma [CA23] [12]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Vandetanib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [13]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Vandetanib and Eribulin. Breast cancer [2C60-2C6Y] [10]
Talazoparib DM1KS78 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [14]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Vandetanib and Bosutinib. Breast cancer [2C60-2C6Y] [10]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [15]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [12]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Vandetanib and Osilodrostat. Cushing syndrome [5A70] [10]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Vandetanib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [16]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Vandetanib and Deutetrabenazine. Dystonic disorder [8A02] [10]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Vandetanib and Ingrezza. Dystonic disorder [8A02] [10]
Cenobamate DM8KLU9 Moderate Increased metabolism of Vandetanib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Vandetanib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [9]
Ripretinib DM958QB Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [9]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [18]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Vandetanib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Vandetanib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Aliskiren DM1BV7W Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [10]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Naloxegol DML0B41 Minor Decreased clearance of Vandetanib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [20]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Vandetanib and Crizotinib. Lung cancer [2C25] [10]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Vandetanib and Osimertinib. Lung cancer [2C25] [10]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Vandetanib and Selpercatinib. Lung cancer [2C25] [10]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Vandetanib and Lumefantrine. Malaria [1F40-1F45] [9]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Vandetanib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [10]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Vandetanib and Idelalisib. Mature B-cell leukaemia [2A82] [21]
GDC-0199 DMH0QKA Major Decreased clearance of Vandetanib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [9]
IPI-145 DMWA24P Moderate Increased metabolism of Vandetanib caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [22]
Arry-162 DM1P6FR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Arry-162. Melanoma [2C30] [9]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Vandetanib and LGX818. Melanoma [2C30] [10]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vandetanib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [11]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Vandetanib and Panobinostat. Multiple myeloma [2A83] [10]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Siponimod. Multiple sclerosis [8A40] [9]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Fingolimod. Multiple sclerosis [8A40] [10]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ozanimod. Multiple sclerosis [8A40] [10]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Vandetanib and Romidepsin. Mycosis fungoides [2B01] [10]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Vandetanib and Rucaparib. Ovarian cancer [2C73] [10]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Vandetanib and Triclabendazole. Parasitic worm infestation [1F90] [10]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Vandetanib and Pimavanserin. Parkinsonism [8A00] [10]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Vandetanib and Macimorelin. Pituitary gland disorder [5A60-5A61] [23]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lefamulin. Pneumonia [CA40] [10]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Vandetanib and Degarelix. Prostate cancer [2C82] [10]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Vandetanib and ABIRATERONE. Prostate cancer [2C82] [10]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Vandetanib and Enzalutamide. Prostate cancer [2C82] [10]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Vandetanib and Relugolix. Prostate cancer [2C82] [10]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Vandetanib and Amisulpride. Schizophrenia [6A20] [10]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Asenapine. Schizophrenia [6A20] [10]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vandetanib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Vandetanib and Pitolisant. Somnolence [MG42] [10]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Vandetanib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [10]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Vandetanib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [24]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [9]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Cabozantinib. Thyroid cancer [2D10] [10]
⏷ Show the Full List of 60 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Brushite E00392 104805 Diluent
Crospovidone E00626 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Vandetanib 100 mg tablet 100 mg Oral Tablet Oral
Vandetanib 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
6 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
7 FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
8 ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer. 2006 Jan 15;118(2):483-9. doi: 10.1002/ijc.21340.
9 Cerner Multum, Inc. "Australian Product Information.".
10 Canadian Pharmacists Association.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
14 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
15 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
16 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
17 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
18 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
19 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
20 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
21 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
22 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
23 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
24 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.